单核细胞趋化蛋白-1在终末期肾病血液透析患者中的检测及意义

The levels and role of MCP - 1 in end stage renal disease patients undergoing hemodialysis

目的探讨终末期肾病血液透析患者血浆单核细胞趋化蛋白-1（MCP-1）的水平及其意义。方法对本院维持性血液透析患者66例及健康志愿者22例，用ELISA法测定血浆MCP-1水平，用全自动生化仪测定血清总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白-胆固醇（HDL—C）、低密度脂蛋白-胆固醇（LDL—C）、血肌酐（Scr）与血白蛋白（ALB）值。比较其结果并分析其意义。结果血液透析组血浆MCP—1水平（115．9pg／ml±10．3pg／ml）明显高于对照组（60．3pg／ml±8．4pg／m1），其差异有统计学意义（P〈0．05）。血液透析合并冠心病组血浆MCP-1水平明显高于非合并冠心病组[（136．2±11．7）pg／ml vs（91．6±9．4）pg／ml，P〈0．05]。结论终末期。肾病血液透析患者血浆MCP-1水平显著高于正常人，合并冠心病患者血浆MCP-1水平更高，提示MCP-1水平升高与肾功能衰竭有一定关系，且是合并冠心病的重要危险因素。

Objectives To investigate the plasma level and role of monocyte chemoattractant protein - 1 （ MCP - 1 ） in end stage renal disease （ESRD） patients undergoing hemodialysis. Methods Plasma MCP - 1 was measured by sandwich ELISA and the serum total cholesterol, triglyceride, high density lipoprotein - cholesterol, low density lipoprotein - cholesterol, serum creatinine, blood albumin of 66 maintenance hemodialysis patients in our hospital were determined and compared with those of 22 healthy controls. Results The plasma levels of MCP - 1 was obviously elevated in hemodialysis patients （115.9pg/ml ± 10.3 pg/ml）compared with control subjects （60.3 pg/ ml ± 8.4pg/ml）, the difference had statistical significance（ P 〈 0.05 ）. And it was higher in hemodialysis patients with coronary heart disease than that in hemodialysis patients without coronary heart disease[ （136.2 ± 11.7 ）pg/ml vs （91.6 ± 9.4） pg/ml, P 〈 0.05 ]. Conclusions MCP - 1 level in hemodialysis patients was higher than con- trol subjects and it was more increased in hemodialysis patients with coronary heart disease than without. It indicated that the increase of MCP - 1 may be concerned with renal failure and an important risk factor of coronary heart disease.